BBIO Q3 2022 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$338,000-85.6% YoY

Gross Profit

-$401,000-118.6% margin

Operating Income

-$129M-38200.0% margin

Net Income

-$137M-40632.8% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

-99.5%

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$136M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$729M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.1B

Cash & Equivalents

$483M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$338,000	$2M	-85.6%
Gross Profit	-$401,000	$890,000	-145.1%
Operating Income	-$129M	-$149M	+13.6%
Net Income	-$137M	-$156M	+11.9%

Revenue Segments

License and Service

$338,000100%